Skip to main content
    E

    Enanta Pharmaceuticals Inc (ENTA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.67
    -0.32 (-2.91%)

    Market Cap: $320.09M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Enanta Pharmaceuticals Inc (ENTA) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Enanta Pharmaceuticals (ENTA) to earn -$2.37 per share in the fiscal year ending Sep 30, 2027, on revenue of $63.74M. Of 6 analysts, 6 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Sep 30, 2027 were revised up and 2 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 6 ratings average 1.83, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy116.7%
    Buy583.3%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    6

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    Fiscal year ending Sep 30, 2027
    -$2.37
    EPS consensus, revenue $63.74M
    Next report
    Feb 8, 2027
    Estimated
    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Sep 30, 2027-$2.37-$3.08 to -$1.755$63.74M$53.19M to $77.00M5

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.41-$0.48 to -$0.332$16.25M$14.50M to $18.00M2

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Sep 30, 202702
    Quarter ending Dec 31, 202601

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Sep 30, 2027 has worsened from -$1.98.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Sep 30, 2027-$2.37-$2.37-$2.37-$2.07-$1.98N/A
    Quarter ending Dec 31, 2026-$0.41-$0.37-$0.37-$0.37-$0.37N/A

    Frequently Asked Questions About ENTA

    What is the ENTA stock forecast?

    Consensus analyst estimates put Enanta Pharmaceuticals's EPS at -$2.37 for the fiscal year ending Sep 30, 2027, on revenue of $63.74M. The consensus rating from 6 analysts is Buy.

    How do analysts rate ENTA stock?

    Of 6 analysts covering Enanta Pharmaceuticals, 1 rates it Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from ENTA next year?

    For the fiscal year ending Sep 30, 2027, the consensus EPS estimate is -$2.37, with estimates from -$3.08 to -$1.75 from 5 analysts.

    What revenue do analysts expect from Enanta Pharmaceuticals next year?

    For the fiscal year ending Sep 30, 2027, the consensus revenue estimate is $63.74M, with estimates from $53.19M to $77.00M.

    How many analysts cover ENTA?

    6 analysts rate Enanta Pharmaceuticals stock, and 5 analysts estimate its EPS for the fiscal year ending Sep 30, 2027.